Relevant bibliographies by topics / 17-OHP

Contents

  1. Journal articles
  2. Books
  3. Book chapters

Academic literature on the topic '17-OHP'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '17-OHP.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "17-OHP"

1

Ransom, Carla E., Jeanette R. Chin, Hilary A. Roeder, Tammy R. Sinclair, R. Phillips Heine, and Amy P. Murtha. "The Influence of Prior Obstetrical History on Current 17-Hydroxyprogesterone Caproate Use." Journal of Pregnancy 2011 (2011): 1–4. http://dx.doi.org/10.1155/2011/286483.

Full text
Abstract:
Objective. To determine if gestational age of prior preterm delivery influences a woman's receipt of 17-hydroxyprogesterone caproate (17-OHP-C).Methods. Retrospective cohort of women eligible for 17-OHP-C at Duke Obstetrics Clinic were identified by medical record review. Sociodemographic and clinical characteristics were abstracted.Results. Of 104 eligible subjects, 82 (78.8%) were offered 17-OHP-C. Of these, thirty-four (41.5%) declined. The median gestational age of the most recent preterm delivery was significantly lower among subjects who accepted 17-OHP-C as compared to those who declined (28.7 vs. 34.0 weeks,P=.02) and in subjects offered 17-OHP-C compared to those not offered 17-OHP-C (30.2 vs. 36.0 weeks,P=.03). Subjects not offered 17-OHP-C were more likely to have had an interval term delivery (31.8% vs. 9.7%,P=.009)Conclusion. Women with earlier preterm deliveries were more likely to be offered and accept 17-OHP-C. Prior obstetric history may influence both providers' and patients' willingness to discuss and/or accept 17-OHP-C.
APA, Harvard, Vancouver, ISO, and other styles
2

Şahin, Yilmaz, Demet Ayata, and Fahrettin Keleştimur. "Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome." European Journal of Endocrinology 136, no. 4 (April 1997): 410–15. http://dx.doi.org/10.1530/eje.0.1360410.

Full text
Abstract:
Abstract Objective: To determine whether hyperinsulinism affects cytochrome P450c 17α activity by investigating the correlation between 17–hydroxyprogesterone (17–OHP) hyper-responsiveness to the gonadotropin-releasing hormone (GnRH) agonist, buserelin, and the insulin response to oral glucose in polycystic ovary syndrome (PCOS). Design: Ultrasound, clinical and hormonal parameters were used to define PCOS in this prospective clinical study. We investigated the correlation between the 17–OHP response to buserelin testing and the insulin response to oral glucose in PCOS. Methods: Twenty-eight women with PCOS and eighteen normal women were included in the study. 17–OHP response to buserelin, and insulin and C–peptide responses to oral glucose were measured. Results: Twenty–live women with PCOS had an increased 17–OHP response. The PCOS patients showed significantly higher mean post–glucose load insulin and C–peptide levels than controls (P<0·05). No significant correlations were found between basal 17–OHP and fasting insulin or fasting C–peptide, between peak 17–OHP and fasting insulin, peak insulin or peak C–peptide, between 17–OHP area under the curve (AUC) and insulin AUC or C–peptide AUC, and between percent increment in 17–OHP and insulin AUC or C–peptide AUC (P >0·05). Conclusions: Lack of a relationship between the 17–OHP response to the GnRH agonist buserelin and hyperinsulinism suggests that hyperinsulinism may not play a role in the dysregulation of the cytochrome P450c17α enzyme seen in PCOS. European Journal of Endocrinology 136 410–415
APA, Harvard, Vancouver, ISO, and other styles
3

Sólyom, J., G. Gács, K. Keszei, K. Láng, J. Örley, I. Petheö, and L. Ságodi. "Detection of late-onset adrenal hyperplasia in girls with peripubertal virilization." Acta Endocrinologica 115, no. 3 (July 1987): 413–18. http://dx.doi.org/10.1530/acta.0.1150413.

Full text
Abstract:
Abstract. We investigated the value of serum levels of adrenal steroids (dehydroepiandrosterone sulphate, testosterone, 17-hydroxyprogesterone, cortisol) in the identification in peripubertal females with late-onset congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Among 68 females (age 3–18 years) with virilization in childhood, peripubertally or postpubertally, we selected 21 girls for an ACTH test by measurement of basal blood-spot or serum 17-hydroxyprogesterone (17-OHP) levels. Eight of 21 patients had supranormal post-ACTH serum 17-OHP concentration (57–153 nmol/l) with low normal cortisol concentration. All of them had supranormal basal and post-ACTH 17-OHP to cortisol ratios. These data show a relatively high incidence (about 12%) of mild 21-hydroxylase deficiency among prepubertal and adolescent girls with virilization. It is concluded that the first step in the investigation of peripubertally virilized girls should be the determination of serum 17-OHP and cortisol. Patients with basal morning 17-OHP concentration and 17-OHP to cortisol ratio above reference range should be given an ACTH test.
APA, Harvard, Vancouver, ISO, and other styles
4

Plavšić, V., D. Rogić, M. Dumić, J. Ille, Lj Brkljačić, and V. Latin. "Interferences with Determination of 17-Hydroxyprogesterone in Amniotic Fluid." Clinical Chemistry 37, no. 12 (December 1, 1991): 2154–55. http://dx.doi.org/10.1093/clinchem/37.12.2154.

Full text
Abstract:
Abstract Continuing our work on the problems of congenital adrenal hyperplasia (CAH) (1, 2), we have established reference values for 17-hydroxyprogesterone (17-OHP) and androstenedione (Δ4) in amniotic fluid(AF) and done 12 successful prenatal diagnoses in families at risk for CAH (3). 17-OHP was determined in the AFs of 105 women in the second trimester of pregnancy with a kit from Sorin-Biomedica (Saluggia, Italy; tritium-labeled 17-OHP, ether extraction). In another 80 pregnant women, 17-OHP was determined with a new Sorin-Biomedica kit (iodine-labeled 17-OHP, ether extraction); a DPC Coat-A-Count kit (Diagnostic Products Corp., Los Angeles, CA), with and without ether extraction; and a CIS Bio International (Gif-sur-Yvette Cedex, France) coated-tubes kit, with and without ether extraction(Table 1).
APA, Harvard, Vancouver, ISO, and other styles
5

Schreiner, Felix, Magdalini Tozakidou, Rita Maslak, Ute Holtkamp, Michael Peter, Bettina Gohlke, and Joachim Woelfle. "Functional glucocorticoid receptor gene variants do not underlie the high variability of 17-hydroxyprogesterone screening values in healthy newborns." European Journal of Endocrinology 160, no. 4 (April 2009): 667–73. http://dx.doi.org/10.1530/eje-08-0639.

Full text
Abstract:
Objective17-Hydroxyprogesterone (17-OHP) screening for classical congenital adrenal hyperplasia (CAH) is part of many newborn screening programs worldwide. Cut-off values are relatively high, and screening sensitivity does not reach 100%. Recently, the glucocorticoid receptor (GR) N363S-variant has been linked to relatively low degree of virilization and comparatively lower 17-OHP serum concentrations in clinically diagnosed female CAH patients. We sought to determine whether functional GR gene variants, either increasing (N363S, BclI) or decreasing GR sensitivity (R23K), underlie the variable 17-OHP screening levels in healthy newborns.DesignGR genotypes were compared with 17-OHP screening values in 1000 random samples from routine screening. 17-OHP was measured by conventional immunoassay (TRFIA) and a liquid chromatography–tandem mass spectrometry method (LC–MS/MS), which has been shown to increase screening specificity by steroid profiling and avoiding cross-reactions of the 17-OHP-antibody.ResultsThere was no significant association of 17-OHP with GR genotypes, even after inclusion of gestational and postnatal age as covariates. However, among LC–MS/MS steroid measurements, we observed some unexpected trends, including lower 11-deoxycortisol concentrations in both 363S- and 23K-carriers. For carriers of the frequent BclI variant, linear regression analysis revealed a significant increase of 4-androstenedione levels with every mutant allele inherited.ConclusionsFunctional GR variants do not underlie the variation of 17-OHP values observed in healthy individuals. However, whether and to which extent genetically determined differences in individual GR sensitivity influence 17-OHP screening levels in conditions of a pathological hypothalamus-pituitary-adrenal gland-axis stimulation and thus may explain false-negative screening results in those affected by CAH remains to be investigated.
APA, Harvard, Vancouver, ISO, and other styles
6

Cavarzere, Paolo, Dinane Samara-Boustani, Isabelle Flechtner, Michèle Dechaux, Caroline Elie, Véronique Tardy, Yves Morel, and Michel Polak. "Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia." European Journal of Endocrinology 161, no. 2 (August 2009): 285–92. http://dx.doi.org/10.1530/eje-09-0145.

Full text
Abstract:
ObjectiveNeonatal screening for congenital adrenal hyperplasia (CAH) is characterized by a high false-positive rate, mainly among preterm and low birth weight infants. The aims of this study were to describe a subgroup of infants with transient serum hyper-17-hydroxyprogesteronemia (hyper-17-OHPemia) and to compare them with false positive and affected by 21-hydroxylase deficiency newborns.MethodsWe retrospectively analyzed the clinical data of all newborns positive at CAH neonatal screening, who were referred to our hospital to confirm the diagnosis from 2002 to 2006. They were submitted to clinical investigations and blood tests to evaluate 17-hydroxyprogesterone (17-OHP), renin, and electrolyte levels. CAH-unaffected newborns with increased serum 17-OHP were submitted to strict follow-up monitoring, which included an ACTH-stimulating test and genetic analysis of the 21-hydroxylase gene, until serum 17-OHP decreased.ResultsThirty-seven newborns with gestational ages ranging from 33 to 40 weeks were studied. Eight infants (three male and five female) were affected by CAH (serum 17-OHP: 277.5 (210–921) nmol/l), 14 (ten male and four female) were false positives (17-OHP: 3.75 (0.3–8.4) nmol/l), and 15 (ten male and five female) showed a serum hyper-17-OHPemia (17-OHP: 15.9 (9.9–33) nmol/l). No mutations of the 21-hydroxylase gene were found in infants with hyper-17-OHPemia and their serum 17-OHP levels were normalized by the third month of life.ConclusionWe identified a population of infants with transient serum hyper-17-OHPemia, and no clinical signs of disease or 21-hydroxylase gene mutations. No further investigations are necessary after birth in these newborns if 17-OHP levels decrease, other confirmatory tests such as ACTH-stimulation test or genotyping analysis are necessary only if symptoms appear.
APA, Harvard, Vancouver, ISO, and other styles
7

Wallace, A. M., J. Beesley, M. Thomson, C. A. Giles, A. M. Ross, and N. F. Taylor. "Adrenal status during the first month of life in mature and premature human infants." Journal of Endocrinology 112, no. 3 (March 1987): 473–80. http://dx.doi.org/10.1677/joe.0.1120473.

Full text
Abstract:
ABSTRACT Measurements of (a) 17-hydroxyprogesterone (17-OHP) in blood collected onto filter paper after heel puncture by lancet and (b) steroid metabolites in random collections of urine, were made in human infants born from 25 weeks of gestation onwards. The concentration of 17-OHP in blood eluted from filter paper samples was inversely related to both gestational age and birth weight. In mature infants, 17-OHP concentrations fell rapidly soon after birth, whereas concentrations remained high over the first month of life in infants born earlier than 33 weeks of gestation. Sulphated urinary steroids were identified as having a 3β-hydroxy-5-ene structure and although the pattern of excretion was similar in mature and premature infants, significantly higher concentrations were found in the premature group. Steroid metabolites normally present when concentrations of circulating 17-OHP are increased due to 21-hydroxylase deficiency were not detectable in urine samples collected from infants born prematurely. Where direct comparison of 17-OHP in blood spots and urinary steroid metabolites was possible, the concentrations of 17-OHP in blood samples paralleled 3β-hydroxy-5-ene steroid metabolites in urine. The results suggest that a circulating cross-reacting 3β-hydroxy-5-ene steroid may be responsible for increased concentrations of 17-OHP in infants born prematurely. Increased concentrations of both 17-OHP in blood spots and steroid sulphates in urine were associated with stress in premature, but not in more mature, infants suggesting that in infants born prematurely postnatal stress may delay adrenal maturation. J. Endocr. (1987) 112, 473–480
APA, Harvard, Vancouver, ISO, and other styles
8

Maas, Kevin H., Sandy S. Chuan, Heidi Cook-Andersen, H. Irene Su, A. Duleba, and R. Jeffrey Chang. "Relationship Between 17-Hydroxyprogesterone Responses to Human Chorionic Gonadotropin and Markers of Ovarian Follicle Morphology in Women With Polycystic Ovary Syndrome." Journal of Clinical Endocrinology & Metabolism 100, no. 1 (January 1, 2015): 293–300. http://dx.doi.org/10.1210/jc.2014-2956.

Full text
Abstract:
Abstract Context: Women with polycystic ovary syndrome (PCOS) have increased 17-hydroxyprogesterone (17-OHP) responses to gonadotropin stimulation although individual variability is substantial, as reflected by exaggerated as well as normal responses. The relationship between 17-OHP responses to gonadotropin stimulation and markers of ovarian function has not been assessed. Objective: To determine whether 17-OHP responses are associated with antral follicle count (AFC), anti-Mullerian hormone (AMH), or inhibin B (Inh B) levels in PCOS and normal women. Design: Prospective study. Setting: Research center at an academic medical center. Participants: Women with PCOS (n = 18) and normal controls (n = 18). Interventions: Blood samples were obtained before and 24 hours after administration of 25 μg recombinant-human chorionic gonadotropin. Ovarian imaging was conducted with three-dimensional pelvic ultrasound. Main Outcome Measures: Basal and stimulated levels of 17-OHP, androgens, estrogen, AMH, Inh B, and AFC. Results: In women with PCOS, 17-OHP responses were heterogeneous and inversely correlated with AMH and Inh B levels, but not AFC. In a subgroup of PCOS women with exaggerated 17-OHP responses, AMH levels were equivalent to that of normal women. In PCOS women with normal 17-OHP responses, AMH levels were markedly elevated. Conclusion: Based on heterogeneous 17-OHP responses to human chorionic gonadotropin in women with PCOS, AMH levels are inversely linked to ovarian androgen production while positively correlated with AFC. These findings suggest that in PCOS, AMH production may reflect redistribution of the follicle population or regulation by intraovarian mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
9

Ionova, T. A., N. Iu Kalinchenko, A. N. Tiul'pakov, and A. N. Nizhnik. "The comparative assessment of the effectiveness of immunoanalysis and tandem mass spectrometry applied for re-testing the children with suspected congenital adrenal cortical hyperplasia." Problems of Endocrinology 59, no. 2 (April 15, 2013): 12–18. http://dx.doi.org/10.14341/probl201359212-18.

Full text
Abstract:
Congenital adrenal cortical hyperplasia (CAH) is one of the commonest endocrine pathologies in the children. Screening newborn infants for CAH is currently based on the measurement of 17-hydroxyprogesterone (17-OHP) levels in blood spots using the immunoenzymatic assay. However, this techniques is known to suffer relatively low specificity accounting for the high percentage of false-positive results. We compared two 17-OHP measurement tecniques, immunoenzymatic assay and liquid chromatography-tandem mass spectrometry (LC-MS/MS) employed for the additional examination of the children in whom screening for CAH revealed the enhanced blood 17-OHP levels. The study included 50 patients at the age from 7 days to 1.5 months born at different gestational ages. 17-OHP levels were measured in all of them using the immunoenzymatic assay and LC-MS/MS. The results of the study indicate that the latter technique should be regarded as the method of choice for the confirmation of diagnosis of CAH. The absence of clinical manifestations of 21-hydroxylase deficiency in the patients in whom the immunoenzymatic assay reveals the enhanced levels of 17-OHP whereas the LC-MS/MS method demonstrates the normal or only slightly elevated concentrations of 17-OHP allows to exclude diagnosis of CAH. The gestational age of the infant is the key factor in the choice of the upper threshold level of 17-OHP for the purpose of screening; the child's body weight is of low diagnostic value. The 17-OHP levels measured by LC-MS/MS in the boys may be slightly higher than the reference values compared with the girls.
APA, Harvard, Vancouver, ISO, and other styles
10

Hàn, Ngọc Thùy Dương, Thị Ngọc Lan Hoàng, Thị Thu Hiền Đào, Phạm Sỹ Cường Lê, Văn Đức Phạm, Danh Cường Trần, and Kim Phượng Đoàn Thị. "Phân tích một số yếu tố ảnh hưởng đến nồng độ 17-hydroxyprogesteron trong sàng lọc sơ sinh bệnh tăng sản thượng thận bẩm sinh." Tạp chí Phụ sản 19, no. 4 (March 7, 2022): 25–28. http://dx.doi.org/10.46755/vjog.2021.4.1319.

Full text
Abstract:
Mục tiêu: Đánh giá mối liên quan giữa các yếu tố cân nặng lúc sinh, giới tính, tuổi lấy mẫu xét nghiệm và tiền sử mẹ sử dụng thuốc chứa corticosteroids với nồng độ 17-OHP sàng lọc sơ sinh. Đối tượng và phương pháp: Nghiên cứu mô tả cắt ngang xác định nồng độ 17-OHP từ mẫu máu gót chân bằng phương pháp sắc khí lỏng khối phổ liên tục (LCMS/MS) trên 2894 trẻ sơ sinh. Nhóm nguy cơ thấp và nhóm nguy cơ cao được phân loại dựa trên ngưỡng nồng độ 17-OHP lần lượt là < 30ng/ml và >= 30 ng/ml. Kết quả: Giá trị trung bình của nồng độ 17-OHP trong nghiên cứu là 7,1 ± 9,857 ng/ml. Giới tính không ảnh hưởng đáng kể đến nồng độ 17-OHP với p=0,51. Trong khi đó, nồng độ này cao hơn đáng kể ở trẻ sinh nhẹ cân, có điều trị thuốc trong và sau quá trình mang thai với p<0,01. Giữa các nhóm tuổi lấy mẫu khác nhau cũng cho kết quả khác biệt đáng kể đến nồng độ 17-OHP ở trẻ sơ sinh. Kết luận: Nồng độ 17-OHP ở mẫu giấy thấm máu gót của trẻ sơ sinh chịu sự ảnh hưởng của các yếu tố như cân nặng lúc sinh, tuổi lấy mẫu xét nghiệm và tiền sử dùng thuốc chứa corticosteroids của mẹ. Nồng độ 17-OHP không bị ảnh hưởng bởi giới tính của trẻ. Nồng độ 17-OHP có xu hướng giảm khi cân nặng của trẻ sơ sinh tăng lên; tăng khi có tiền sử dùng thuốc chứa corticosteroids.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "17-OHP"

1

ESO-OHP Workshop on the Optimization of the Use of CCD Detectors in Astronomy (1986 Observatoire de Haute-Provence). ESO-OHP Workshop on the Optimization of the Use of CCD Detectors in Astronomy: Held at Observatoire de Haute-Provence, 17-19 June 1986 : proceedings. Garching bei München: European Southern Observatory, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

ESO-OHP workshop on the optimization of the use of CCD detectors in Astronomy: Held at Obeservatoire de Haute-Provence 17-19 June 1986. München: ESO, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

ESO-OHP Workshop on the Optimization of the Use of CCD Detectors in Astronomy: Held at Observatoire de Haute-Provence, 17-19 June 1986 : Proceedings (ESO conference and workshop proceedings). European Southern Observatory, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "17-OHP"

1

"17-OHP." In Springer Reference Medizin, 1777. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_301248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Caquet, René. "Progestérone 17 hydroxy (17-OHP)." In Guide infirmier des examens de laboratoire, 263–64. Elsevier, 2008. http://dx.doi.org/10.1016/b978-2-294-70220-4.50128-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Caquet, René. "Progestérone 17-hydroxy (17-OHP)." In 250 examens de laboratoire, 297–98. Elsevier, 2010. http://dx.doi.org/10.1016/b978-2-294-71033-9.50167-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dumesic, Daniel, and Zain Al-Safi. "Laboratory Evaluation." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple, 1277–86. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0154.

Full text
Abstract:
A variety of laboratory assessment and imaging studies can be ordered to guide the management of patients with suspected endocrine abnormality. These are selected based on the clinical presentation. In this chapter, we thereby classify them into hormonal evaluation (e.g. β‎-hCG, oestradiol, progesterone, LH and FSH, androgens (testosterone, DHEAS), 17 α‎-hydroxyprogesterone (17 OHP), prolactin, growth hormone, anti-Mullerian hormone (AMH), thyroid hormone, cortisol), imaging studies (e.g. head, ovarian, adrenal, bone density, and thyroid), and other assessments (e.g. karyotype, fragile X testing, autoimmune testing, insulin resistance testing) that are helpful in diagnosing these conditions and evaluating for other associated abnormalities. A full references list and illustrative tables provide further reading and information.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '17-OHP' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography